Remicade patents?

Short answer: there are multiple Remicade (infliximab) patent families across jurisdictions. Some core patents have expired in major markets, but there are still patents and regulatory exclusivities that have provided or can provide protection in certain places and at certain times. The exact status depends on the country and the specific patent family (composition of matter, manufacturing/formulation, use, etc.).

What to know at a high level
- What Remicade patents cover
- Antibody itself (composition of matter) and related infliximab sequences
- Manufacturing and purification processes
- Formulations and dosage forms
- Methods of use (e.g., certain diseases such as Crohn’s disease, rheumatoid arthritis, ulcerative colitis, etc.)
- How protection can be maintained
- Patent protection (country-by-country; some have expired, some may still be active)
- Regulatory exclusivity for biologics (data exclusivity) which blocks others from relying on Remicade’s safety/efficacy data for a period in a given market
- Litigation/patent litigation outcomes can affect timing of biosimilar entry
- Practical reality
- In the U.S., many core infliximab patents have expired, enabling biosimilar competition, but some patents and/or exclusivities can still affect entry in certain contexts.
- In the EU and other regions, biosimilars entered earlier in some markets, but the patent landscape still varies by country and by patent family.
- The first infliximab biosimilars entered the U.S. market around 2016 after patent disputes; EU introductions varied by country and year.

Where to check current, precise status
- United States: FDA Purple Book (the official source for biological product information, including patent and exclusivity status for Remicade/infliximab and its biosimilars). This is the best single source for US patent/exclusivity data.
- Patent status databases: Google Patents, Espacenet, USPTO Patent Full-Text database. Searching for infliximab or Remicade patent families will give you the active/expired status and expiry dates.
- Europe: EMA/European Patent Office resources and national patent offices; check specific country patent status and any litigation outcomes.
- If you want, I can pull up the current US Purple Book entry and a few key patent family numbers (with status and expiry dates) and summarize them for you.

Would you like me to look up current patent and exclusivity status for Remicade in a specific jurisdiction (US, EU, or another country) and provide a concise list of active patent numbers and their expiry dates? If yes, tell me which jurisdiction you’re interested in.